Lipid Nanoparticles for Short Interfering RNA Delivery

Abstract The discovery of RNA interference (RNAi) in mammalian cells has created a new class of therapeutics based on the reversible silencing of specific disease-causing genes. This therapeutic potential depends on the ability to deliver inducers of RNAi, such as short-interfering RNA (siRNA) and micro-RNA (miRNA), to cells of target tissues. This chapter reviews various challenges and delivery strategies for siRNA, with a particular focus on the development of lipid nanoparticle (LNP) delivery technologies. Currently, LNP delivery systems are the most advanced technology for systemic delivery of siRNA, with numerous formulations under various stages of clinical trials. We also discuss methods to improve gene silencing potency of LNP-siRNA, as well as application of LNP technologies beyond siRNA to the encapsulation of other nucleic acids such as mRNA and clustered regularly interspaced short palindromic repeats (CRISPR).

[1]  B. de Kruijff,et al.  The polymorphic phase behaviour of phosphatidylethanolamines of natural and synthetic origin. A 31P NMR study. , 1978, Biochimica et biophysica acta.

[2]  M. Johnston,et al.  Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. , 2006, Biochimica et biophysica acta.

[3]  A. Bangham,et al.  Diffusion of univalent ions across the lamellae of swollen phospholipids. , 1965, Journal of molecular biology.

[4]  J. Kamps,et al.  The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse. , 2005, Biochemical and biophysical research communications.

[5]  C. Streffer,et al.  The vascular architecture of human xenotransplanted tumors: histological, morphometrical, and ultrastructural studies , 2005, Journal of Cancer Research and Clinical Oncology.

[6]  R. Jain,et al.  Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. , 1994, Cancer research.

[7]  Rudolf Jaenisch,et al.  One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering , 2013, Cell.

[8]  Z. Paroo,et al.  Biodistribution of phosphodiester and phosphorothioate siRNA. , 2004, Bioorganic & medicinal chemistry letters.

[9]  Timo Laaksonen,et al.  Gold nanoparticles enable selective light-induced contents release from liposomes. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[10]  Svetlana Shulga Morskaya,et al.  Harnessing a Physiologic Mechanism for siRNA Delivery With Mimetic Lipoprotein Particles , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  P. Cullis,et al.  Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. , 2001, Biochimica et biophysica acta.

[12]  J. Hainfeld,et al.  Gold nanoparticle imaging and radiotherapy of brain tumors in mice. , 2013, Nanomedicine.

[13]  Wong,et al.  Biological barriers to cellular delivery of lipid-based DNA carriers. , 1999, Advanced drug delivery reviews.

[14]  K. Giese,et al.  Delivery of therapeutic siRNA to the lung endothelium via novel Lipoplex formulation DACC. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  Theresa M Allen,et al.  Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. , 2004, Biochimica et biophysica acta.

[16]  L. Marraffini,et al.  CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea , 2010, Nature Reviews Genetics.

[17]  G. Molema,et al.  In Vivo Characteristics of Cationic Liposomes as Delivery Vectors for Gene Therapy , 2002, Pharmaceutical Research.

[18]  S. Kügler,et al.  Transfection of "naked" siRNA results in endosomal uptake and metabolic impairment in cultured neurons. , 2004, Biochemical and biophysical research communications.

[19]  S. Skinner,et al.  Microvascular architecture of experimental colon tumors in the rat. , 1990, Cancer research.

[20]  R. Scheule,et al.  Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung. , 1997, Human gene therapy.

[21]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[22]  Robert Langer,et al.  Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates , 2008, Proceedings of the National Academy of Sciences.

[23]  J. Dye,et al.  Ebola virus entry requires the cholesterol transporter Niemann-Pick C1 , 2011, Nature.

[24]  P. Cullis,et al.  The polymorphic phase behavior of mixed phosphatidylserine-phosphatidylethanolamine model systems as detected by 31P-NMR. Effects of divalent cations and pH , 1981 .

[25]  K. Kono,et al.  Preparation and characterization of complexes of liposomes with gold nanoparticles. , 2008, Colloids and surfaces. B, Biointerfaces.

[26]  U. Nielsen,et al.  Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.

[27]  Y. Barenholz,et al.  Ammonium Sulfate Gradients for Efficient and Stable Remote Loading of Amphipathic Weak Bases into Liposomes and Ligandoliposomes. , 1994 .

[28]  A. Aigner,et al.  RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo , 2005, Gene Therapy.

[29]  R. Leventis,et al.  Interactions of cationic lipid vesicles with negatively charged phospholipid vesicles and biological membranes. , 1988, Biochemistry.

[30]  G. Storz,et al.  Regulatory RNAs in Bacteria , 2009, Cell.

[31]  J F Hainfeld,et al.  Gold nanoparticles: a new X-ray contrast agent. , 2006, The British journal of radiology.

[32]  F. Natt,et al.  siRNA relieves chronic neuropathic pain. , 2004, Nucleic acids research.

[33]  Yu-cheng Tseng,et al.  Lipid-based systemic delivery of siRNA. , 2009, Advanced drug delivery reviews.

[34]  K. Mislick,et al.  Evidence for the role of proteoglycans in cation-mediated gene transfer. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. Debs,et al.  Proteoglycans Mediate Cationic Liposome-DNA Complex-based Gene Delivery in Vitro and in Vivo * , 1998, The Journal of Biological Chemistry.

[36]  J. Rosenecker,et al.  Expression of therapeutic proteins after delivery of chemically modified mRNA in mice , 2011, Nature Biotechnology.

[37]  N. Zhong,et al.  Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque , 2005, Nature Medicine.

[38]  L. Jeffs,et al.  A Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA , 2005, Pharmaceutical Research.

[39]  U. Beisiegel,et al.  The LDL–receptor–related protein, LRP, is an apolipoprotein E-binding protein , 1989, Nature.

[40]  Rob Lambkin-Williams,et al.  A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus , 2010, Proceedings of the National Academy of Sciences.

[41]  G. Hutvagner,et al.  A microRNA in a Multiple-Turnover RNAi Enzyme Complex , 2002, Science.

[42]  William Y. Kim,et al.  Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[43]  D. C. Litzinger.  Limitations of Cationic Liposomes for Antisense Oligonucleotide Delivery in Vivo , 1997 .

[44]  Joshua C. Johnson,et al.  Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study , 2010, The Lancet.

[45]  A. Klippel,et al.  A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium , 2006, Gene Therapy.

[46]  K. Makino,et al.  Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product , 1987, Journal of bacteriology.

[47]  G. Christofori,et al.  Polyethylenimine (PEI) is a simple, inexpensive and effective reagent for condensing and linking plasmid DNA to adenovirus for gene delivery , 1997, Gene Therapy.

[48]  Daniel G. Anderson,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[49]  B. Lebleu,et al.  Antibody-targeted liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively inhibit viral replication. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[50]  M. Hope,et al.  The influence of size and composition on the cholesterol mobilizing properties of liposomes in vivo. , 1993, Biochimica et biophysica acta.

[51]  Mark E. Davis,et al.  Effects of Structure of β-Cyclodextrin-Containing Polymers on Gene Delivery , 2001 .

[52]  Svetlana Shulga Morskaya,et al.  RNA Interference-Mediated Silencing of the Respiratory Syncytial Virus Nucleocapsid Defines a Potent Antiviral Strategy , 2009, Antimicrobial Agents and Chemotherapy.

[53]  P. Cullis,et al.  Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. , 2001, Biophysical journal.

[54]  M. Stoffel,et al.  Mechanisms and optimization of in vivo delivery of lipophilic siRNAs , 2007, Nature Biotechnology.

[55]  Qing Ge,et al.  Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[56]  Mark E. Davis,et al.  Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. , 2003, Bioconjugate chemistry.

[57]  K. G. Rajeev,et al.  Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[58]  Anton P. McCaffrey,et al.  In vivo activity of nuclease-resistant siRNAs. , 2004, RNA.

[59]  G. Gregoriadis.  Enzyme entrapment in liposomes. , 1976, Methods in enzymology.

[60]  H. Maeda.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[61]  K. Williams,et al.  Effects of apolipoproteins A-IV and A-I on the uptake of phospholipid liposomes by hepatocytes. , 1989, The Journal of biological chemistry.

[62]  D. Deamer,et al.  Catecholamine uptake and concentration by liposomes maintaining p/ gradients. , 1976, Biochimica et biophysica acta.

[63]  Lois E. H. Smith,et al.  Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. , 2009, Investigative ophthalmology & visual science.

[64]  Mark E. Davis,et al.  Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. , 2005, Cancer research.

[65]  F. Eckstein,et al.  Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes. , 1991, Science.

[66]  M. Krieger,et al.  Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). , 1994, Annual review of biochemistry.

[67]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[68]  F. Natt,et al.  Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[69]  A. Caudy,et al.  Role for a bidentate ribonuclease in the initiation step of RNA interference , 2001 .

[70]  Feng Liu,et al.  Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. , 2005, Advanced drug delivery reviews.

[71]  M. Bally,et al.  Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia , 2004, Cancer Chemotherapy and Pharmacology.

[72]  P. Rabinovich.  Synthetic Messenger RNA and Cell Metabolism Modulation , 2013, Methods in Molecular Biology.

[73]  G Gregoriadis,et al.  Drug entrapment in liposomes , 1973, FEBS letters.

[74]  R. Mahley,et al.  Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. , 1999, Journal of lipid research.

[75]  V. Kunin,et al.  CRISPR — a widespread system that provides acquired resistance against phages in bacteria and archaea , 2008, Nature Reviews Microbiology.

[76]  P. Cullis,et al.  Developments in liposomal drug delivery systems , 2001, Expert opinion on biological therapy.

[77]  R. Hammer,et al.  Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[78]  P. Campochiaro,et al.  Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1 , 2006, Gene Therapy.

[79]  Leaf Huang,et al.  Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. , 2006, Molecular pharmaceutics.

[80]  J. Doudna,et al.  RNA-guided genetic silencing systems in bacteria and archaea , 2012, Nature.

[81]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[82]  M. Bally,et al.  Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. , 1986, Biochimica et biophysica acta.

[83]  G. Weissmann,et al.  The action of steroids and streptolysin S on the permeability of phospholipid structures to cations. , 1965, Journal of molecular biology.

[84]  P. Tan,et al.  Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat , 2005, Gene Therapy.

[85]  Matthias John,et al.  RNAi-mediated gene silencing in non-human primates , 2006, Nature.

[86]  B. Wiedenmann,et al.  Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. , 2008, Cancer research.

[87]  Pradeep Kumar,et al.  Amphiphilic polyethylenimine polymers mediate efficient delivery of DNA and siRNA in mammalian cells. , 2013, Molecular bioSystems.

[88]  John M. Burke,et al.  Extensive phosphorothioate substitution yields highly active and nuclease-resistant hairpin ribozymes. , 1992, Nucleic acids research.

[89]  P. Cullis,et al.  Ionophore-mediated uptake of ciprofloxacin and vincristine into large unilamellar vesicles exhibiting transmembrane ion gradients. , 1998, Biochimica et biophysica acta.

[90]  J. Hainfeld,et al.  The use of gold nanoparticles to enhance radiotherapy in mice. , 2004, Physics in medicine and biology.

[91]  C. van Broeckhoven,et al.  Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. , 2001, Blood.

[92]  G. Weissmann,et al.  Phospholipid spherules (liposomes) as a model for biological membranes. , 1968, Journal of lipid research.

[93]  Sue Hwang,et al.  A New Class of Polymers for the Delivery of Macromolecular Therapeutics , 1999, Nature Biotechnology.

[94]  Matthias John,et al.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.

[95]  C. Robic,et al.  Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. , 2008, Chemical reviews.

[96]  H. Uludaǧ,et al.  Thermodynamics of polyethylenimine-DNA binding and DNA condensation. , 2010, Biophysical journal.

[97]  S. Elbashir,et al.  Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). , 2008, Antiviral research.

[98]  D. Thompson,et al.  Acid-triggered release via dePEGylation of DOPE liposomes containing acid-labile vinyl ether PEG-lipids. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[99]  I. Maclachlan.  Liposomal Formulations for Nucleic Acid Delivery , 2007 .

[100]  R K Jain,et al.  Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.

[101]  Nick V Grishin,et al.  Biochemical identification of Argonaute 2 as the sole protein required for RNA-induced silencing complex activity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[102]  Jianzhu Chen,et al.  Cross-linked Small Polyethylenimines: While Still Nontoxic, Deliver DNA Efficiently to Mammalian Cells in Vitro and in Vivo , 2005, Pharmaceutical Research.

[103]  W. Filipowicz,et al.  Post-transcriptional gene silencing by siRNAs and miRNAs. , 2005, Current opinion in structural biology.

[104]  Phillip D Zamore,et al.  Perspective: machines for RNAi. , 2005, Genes & development.

[105]  Judy Lieberman,et al.  Interfering with disease: a progress report on siRNA-based therapeutics , 2007, Nature Reviews Drug Discovery.

[106]  Zicai Liang,et al.  Elimination pathways of systemically delivered siRNA. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[107]  J. Hecker,et al.  Lipid-mediated delivery of RNA is more efficient than delivery of DNA in non-dividing cells. , 2010, International journal of pharmaceutics.

[108]  K. Miller,et al.  The opposing effects of pressure and general anaesthetics on the cation permeability of liposomes of varying lipid composition. , 1973, Biochimica et biophysica acta.

[109]  Daniel Anderson,et al.  Delivery materials for siRNA therapeutics. , 2013, Nature materials.

[110]  Sung Wan Kim,et al.  Polyethylenimine with acid-labile linkages as a biodegradable gene carrier. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[111]  P. Opolon,et al.  Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. , 2006, Human gene therapy.

[112]  N. Bellocq,et al.  Effects of structure of beta-cyclodextrin-containing polymers on gene delivery. , 2001, Bioconjugate chemistry.

[113]  Wei Tang,et al.  Correction of a genetic disease in mouse via use of CRISPR-Cas9. , 2013, Cell stem cell.

[114]  P. Cullis,et al.  Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles. , 1994, Biochimica et biophysica acta.

[115]  Jeffry D. Sander,et al.  CRISPR-Cas systems for editing, regulating and targeting genomes , 2014, Nature Biotechnology.

[116]  Robert Langer,et al.  Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling , 2013, Nature Biotechnology.

[117]  A. Bangham,et al.  NEGATIVE STAINING OF PHOSPHOLIPIDS AND THEIR STRUCTURAL MODIFICATION BY SURFACE-ACTIVE AGENTS AS OBSERVED IN THE ELECTRON MICROSCOPE. , 1964, Journal of molecular biology.

[118]  Yuhua Wang,et al.  Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[119]  P. Cullis,et al.  On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids , 2001, Gene Therapy.

[120]  Yu-cheng Tseng,et al.  Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[121]  S. Barik,et al.  Inhibition of respiratory viruses by nasally administered siRNA , 2005, Nature Medicine.

[122]  B. Bettencourt,et al.  Safety and efficacy of RNAi therapy for transthyretin amyloidosis. , 2013, The New England journal of medicine.

[123]  Mark E. Davis,et al.  Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA , 2007, Proceedings of the National Academy of Sciences.

[124]  Shigeo Matsuda,et al.  Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo** , 2012, Angewandte Chemie.

[125]  P. Cullis,et al.  Modulation of membrane fusion by asymmetric transbilayer distributions of amino lipids. , 1994, Biochemistry.

[126]  Nicole Rusk.  Microbiology: Prokaryotic RNAi , 2012, Nature Methods.

[127]  P. Cullis,et al.  Ca2+ and pH induced fusion of small unilamellar vesicles consisting of phosphatidylethanolamine and negatively charged phospholipids: a freeze fracture study. , 1983, Biochemical and biophysical research communications.

[128]  I. Wróbel,et al.  Fusion of cationic liposomes with mammalian cells occurs after endocytosis. , 1995, Biochimica et biophysica acta.

[129]  Nathan M Belliveau,et al.  Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA , 2012, Molecular therapy. Nucleic acids.

[130]  Akin Akinc,et al.  Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles , 2013, Molecular therapy. Nucleic acids.

[131]  M. Bally,et al.  The liposomal formulation of doxorubicin. , 2005, Methods in enzymology.

[132]  David P. Bartel,et al.  Passenger-Strand Cleavage Facilitates Assembly of siRNA into Ago2-Containing RNAi Enzyme Complexes , 2005, Cell.

[133]  Hans Clevers,et al.  Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. , 2013, Cell stem cell.

[134]  M. Bally,et al.  Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. , 1995, British Journal of Cancer.

[135]  M. Baker.  Gene editing at CRISPR speed , 2014, Nature Biotechnology.

[136]  C. L. Johnson,et al.  Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice. , 2000, Human gene therapy.

[137]  Francis C Szoka,et al.  Low-pH-sensitive PEG-stabilized plasmid-lipid nanoparticles: preparation and characterization. , 2003, Bioconjugate chemistry.

[138]  A. Lamond,et al.  Highly efficient chemical synthesis of 2'-O-methyloligoribonucleotides and tetrabiotinylated derivatives; novel probes that are resistant to degradation by RNA or DNA specific nucleases. , 1989, Nucleic acids research.

[139]  K. G. Rajeev,et al.  Rational design of cationic lipids for siRNA delivery , 2010, Nature Biotechnology.

[140]  T. Allen,et al.  Ligand-targeted liposomal anticancer drugs. , 2003, Progress in lipid research.

[141]  M. Roberge,et al.  Small molecule ligands for enhanced intracellular delivery of lipid nanoparticle formulations of siRNA. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[142]  G. Klebe,et al.  Targeting the blind spot of polycationic nanocarrier-based siRNA delivery. , 2012, ACS nano.

[143]  P. Cullis,et al.  Lipid polymorphism and the roles of lipids in membranes. , 1986, Chemistry and physics of lipids.

[144]  B. Bettencourt,et al.  Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial , 2014, The Lancet.

[145]  A. Lee,et al.  Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[146]  Marcus Textor,et al.  Triggered release from liposomes through magnetic actuation of iron oxide nanoparticle containing membranes. , 2011, Nano letters.

[147]  T. Allen,et al.  In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. , 2001, Biochimica et biophysica acta.

[148]  D. Friend,et al.  Liposomes containing colloidal gold are a useful probe of liposome-cell interactions. , 1983, Biochimica et biophysica acta.

[149]  I. Maclachlan,et al.  Cationic lipid-mediated transfection of cells in culture requires mitotic activity , 1999, Gene Therapy.

[150]  P. Cullis,et al.  Roles of lipid polymorphism in intracellular delivery. , 2001, Advanced drug delivery reviews.

[151]  F. Szoka,et al.  Steric stabilization of fusogenic liposomes by a low-pH sensitive PEG--diortho ester--lipid conjugate. , 2001, Bioconjugate chemistry.

[152]  J. Northrop,et al.  Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[153]  Sung-Hee Park,et al.  Loading of gold nanoparticles inside the DPPC bilayers of liposome and their effects on membrane fluidities. , 2006, Colloids and surfaces. B, Biointerfaces.

[154]  G. Ying,et al.  INTRAVITREAL INJECTION OF VASCULAR ENDOTHELIAL GROWTH FACTOR SMALL INTERFERING RNA INHIBITS GROWTH AND LEAKAGE IN A NONHUMAN PRIMATE, LASER-INDUCED MODEL OF CHOROIDAL NEOVASCULARIZATION , 2004, Retina.

[155]  Leaf Huang,et al.  Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. , 2009, Molecular pharmaceutics.

[156]  David A Jaffray,et al.  Cellular uptake and transport of gold nanoparticles incorporated in a liposomal carrier. , 2010, Nanomedicine : nanotechnology, biology, and medicine.

[157]  Stefan L Ameres,et al.  Molecular Basis for Target RNA Recognition and Cleavage by Human RISC , 2007, Cell.

[158]  Xiaodong Wang,et al.  Argonaute2 Cleaves the Anti-Guide Strand of siRNA during RISC Activation , 2005, Cell.

[159]  Sarah Seifert,et al.  Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape , 2013, Nature Biotechnology.

[160]  P. Cullis,et al.  Liposomal drug delivery systems: from concept to clinical applications. , 2013, Advanced drug delivery reviews.

[161]  Han-Oh Park,et al.  Chemical modification of siRNAs to improve serum stability without loss of efficacy. , 2006, Biochemical and biophysical research communications.

[162]  M. Bally,et al.  Techniques for encapsulating bioactive agents into liposomes. , 1986, Chemistry and physics of lipids.

[163]  Leaf Huang,et al.  Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[164]  Jennifer Doudna,et al.  RNA-programmed genome editing in human cells , 2013, eLife.

[165]  R. Mahley,et al.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.

[166]  E. Wagner,et al.  Simple modifications of branched PEI lead to highly efficient siRNA carriers with low toxicity. , 2008, Bioconjugate chemistry.

[167]  G. Gregoriadis,et al.  Liposomes as carriers of enzymes or drugs: a new approach to the treatment of storage diseases. , 1971, The Biochemical journal.

[168]  R. Schiffelers,et al.  Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. , 2004, Nucleic acids research.

[169]  F. Liu,et al.  Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[170]  S. Pun,et al.  Self-assembling nucleic acid delivery vehicles via linear, water-soluble, cyclodextrin-containing polymers. , 2004, Current medicinal chemistry.

[171]  F. Natt,et al.  siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain , 2005, Molecular Psychiatry.

[172]  Xudong Yuan,et al.  Recent advances of siRNA delivery by nanoparticles , 2011, Expert opinion on drug delivery.

[173]  Jayanth Panyam,et al.  The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. , 2010, Biomaterials.

[174]  Leaf Huang,et al.  Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. , 2012, Journal of controlled release : official journal of the Controlled Release Society.